Transcriptomic Biomarkers of Cardiovascular Disease

Progress in Cardiovascular Diseases

Volumn 55, Issue 1, 2012, Pages 64-69

  Pedrotty, Dawn M ^a   Morley, Michael P ^a   Cappola, Thomas P ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cardiovascular disease; Genomics biomarkers; Transcriptomics

Indexed keywords

BIOLOGICAL MARKER; DNA; HEMOPROTEIN; MESSENGER RNA; MICRORNA; PROTEIN ST2; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ARTICLE; CARDIAC GRAFT REJECTION; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; HEART FAILURE; HUMAN; HYPERTENSION; REGULATORY DNA SEQUENCE; REGULATORY RNA SEQUENCE; RNA EDITING; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS;

CARDIOVASCULAR DISEASES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIVIDUALIZED MEDICINE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 84864060344     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2012.06.003     Document Type: Article

References (57)

1. Feero W.G., Guttmacher A.E., Collins F.S. Genomic medicine-an updated primer. N Engl J Med 2010, 362:2001-2011.
2. Musunuru K., Kathiresan S. Genetics of coronary artery disease. Annu Rev Genomics Hum Genet 2010, 11:91-108.
3. Cappola T.P., Dorn G.W. Clinical considerations of heritable factors in common heart failure. Circ Cardiovasc Genet 2011, 4:701-709.
4. Ashley E.A., Butte A.J., Wheeler M.T., et al. Clinical assessment incorporating a personal genome. Lancet 2010, 375:1525-1535.
5. Cappola T.P., Margulies K.B. Functional genomics applied to cardiovascular medicine. Circulation 2011, 124:87-94.
6. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006, 354:2463-2472.
7. Wang Z., Gerstein M., Snyder M. RNA-seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009, 10:57-63.
8. Baccarelli A., Rienstra M., Benjamin E.J. Cardiovascular epigenetics. Circ Cardiovasc Genet 2010, 3:567-573.
9. Keren H., Lev-Maor G., Ast G. Alternative splicing and evolution: diversification, exon definition and function. Nat Rev Genet 2010, 11:345-355.
10. Li M., Wang I.X., Li Y., et al. Widespread RNA and DNA sequence differences in the human transcriptome. Science 2011, 333:53-58.
11. Rabani M., Kertesz M., Segal E. Computational prediction of RNA structural motifs involved in posttranscriptional regulatory processes. Proc Natl Acad Sci USA 2008, 105:14885-14890.
12. Small E.M., Frost R.J., Olson E.N. MicroRNAs add a new dimension to cardiovascular disease. Circulation 2010, 121:1022-1032.
13. Rinn J.L., Chang H.Y. Genome regulation by long noncoding RNAs. Annu Rev Biochem 2012, 81:145-166.
14. Valadi H., Ekstrom K., Bossios A., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007, 9:654-659.
15. Mayer G., Muller J., Lunse C.E. Rna diagnostics: real-time RT-PCR strategies and promising novel target RNAs. Wiley interdisciplinary reviews. RNA 2011, 2:32-41.
16. Dewey F.E., Pan S., Wheeler M.T., et al. DNA sequencing: clinical applications of new DNA sequencing technologies. Circulation 2012, 125:931-944.
17. Chen R., Mias G.I., Li-Pook-Than J., et al. Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell 2012, 148:1293-1307.
18. Whitney A.R., Diehn M., Popper S.J., et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003, 100:1896-1901.
19. La Tang Y., Aronow B.J., Sharp F.R. Blood genomic responses differ after stroke, seizures, hypoglycemia, and hypoxia: blood genomic fingerprints of disease. Ann Neurol 2001, 50:699-707.
20. Chon H.G.C., van der Meijden B.B., Dijstelbloem H.M., et al. Broadly altered gene expression in blood leukocytes in essential hypertension is absent during treatment. Hypertension 2004, 43:947-951.
21. Rosenberg S., Elashoff M.R., Beineke P., et al. Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients. Ann Intern Med 2010, 153:425-434.
22. Rockett J.C., Burczynski M.E., Fornace A.J., et al. Surrogate tissue analysis: monitoring toxicant exposure and health status of inaccessible tissues through the analysis of accessible tissues and cells. Toxicol Appl Pharmacol 2004, 194:189-199.
23. Feezor R.J., Baker H.V., Mindrinos M., et al. Whole blood and leukocyte rna isolation for gene expression analyses. Physiol Genomics 2004, 19:247-254.
24. Leek J.T., Scharpf R.B., Bravo H.C., et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet 2010, 11:733-739.
25. Lewis B.P., Shih I.H., Jones-Rhoades M.W., et al. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798.
26. Esquela-Kerscher A., Slack F.J. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
27. Weber J.A., Baxter D.H., Zhang S., et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56:1733-1741.
28. Tsui N.B.Y., Ng E.K.O., Lo Y.M.D. Stability of endogenous and added rna in blood specimens, serum, and plasma. Clin Chem 2002, 48:1647-1653.
29. Kittleson M.M., Ye S.Q., Irizarry R.A., et al. Identification of a gene expression profile that differentiates between ischemic and nonischemic cardiomyopathy. Circulation 2004, 110:3444-3451.
30. Margulies K.B., Matiwala S., Cornejo C., et al. Mixed messages: transcription patterns in failing and recovering human myocardium. Circ Res 2005, 96:592-599.
31. Hannenhalli S., Putt M.E., Gilmore J.M., et al. Transcriptional genomics associates fox transcription factors with human heart failure. Circulation 2006, 114:1269-1276.
32. Chen Y., Park S., Li Y., et al. Alterations of gene expression in failing myocardium following left ventricular assist device support. Physiol Genomics 2003, 14:251-260.
33. Japp A.G., Cruden N.L., Barnes G., et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 2010, 121:1818-1827.
34. Heidecker B., Kittleson M.M., Kasper E.K., et al. Transcriptomic biomarkers for the accurate diagnosis of myocarditis. Circulation 2011, 123:1174-1184.
35. Felker G.M., Hu W., Hare J.M., et al. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine 1999, 78:270-283.
36. Cooper L.T., Baughman K.L., Feldman A.M., et al. Endorsed by the Heart Failure Society of A, the Heart Failure Association of the European Society of C. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the american heart association, the american college of cardiology, and the european society of cardiology. Circulation 2007, 116:2216-2233.
37. Weinberg E.O., Shimpo M., De Keulenaer G.W., et al. Expression and regulation of st2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002, 106:2961-2966.
38. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member st2 in patients with acute dyspnea: results from the pride (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study. J Am Coll Cardiol 2007, 50:607-613.
39. Ky B., French B., McCloskey K., et al. High-sensitivity st2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011, 4:180-187.
40. Sanada S., Hakuno D., Higgins L.J., et al. Il-33 and st2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 2007, 117:1538-1549.
41. Kakkar R., Lee R.T. The il-33/st2 pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov 2008, 7:827-840.
42. Horwitz P.A., Tsai E.J., Putt M.E., et al. Detection of cardiac allograft rejection and response to immunosuppressive therapy with peripheral blood gene expression. Circulation 2004, 110:3815-3821.
43. Deng M.C., Eisen H.J., Mehra M.R., et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006, 6:150-160.
44. Starling R.C., Pham M., Valantine H., et al. Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant 2006, 25:1389-1395.
45. Yamani M.H., Taylor D.O., Haire C., et al. Post-transplant ischemic injury is associated with up-regulated allomap gene expression. Clin Transplant 2007, 21:523-525.
46. Widera C., Gupta S.K., Lorenzen J.M., et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011, 51:872-875.
47. D'Alessandra Y., Devanna P., Limana F., et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 2010, 31:2765-2773.
48. Ji X., Takahashi R., Hiura Y., et al. Plasma mir-208 as a biomarker of myocardial injury. Clin Chem 2009, 55:1944-1949.
49. Corsten M.F., Dennert R., Jochems S., et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease/clinical perspective. Circ Cardiovasc Genet 2010, 3:499-506.
50. Zampetaki A., Kiechl S., Drozdov I., et al. Plasma microRNA profiling reveals loss of endothelial mir-126 and other microRNAs in type 2 diabetes/novelty and significance. Circ Res 2010, 107:810-817.
51. Li S., Zhu J., Zhang W., et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection/clinical perspective. Circulation 2011, 124:175-184.
52. Tijsen A.J., Creemers E.E., Moerland P.D., et al. Mir423-5p as a circulating biomarker for heart failure. Circ Res 2010, 106:1035-1039.
53. Latronico M.V.G., Catalucci D., Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res 2007, 101:1225-1236.
54. Ky B., French B., Levy W.C., et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail 2012, 5:183-190.
55. Freely associating. Nat Genet 1999, 22:1-2.
56. Snyder T.M., Khush K.K., Valantine H.A., et al. Universal noninvasive detection of solid organ transplant rejection. Proc Natl Acad Sci USA 2011, 108:6229-6234.
57. Morrow D.A., de Lemos J.A. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007, 115:949-952.